A patient-driven clinicogenomic partnership for metastatic prostate cancer
Name
1-s2.0-S2666979X22001112-main.pdf
Description
Published version
Size
2.03 MB
Format
Adobe PDF
Checksum (MD5)
a3a9ce3b06f8fb3e75d48e8bd76a07be
Date Issued
2022
Journal
Cell Genomics
Publisher
Elsevier BV
Citation
2022. "A patient-driven clinicogenomic partnership for metastatic prostate cancer." Cell Genomics, 2 (9).
Version
Final published version
Abstract
Molecular profiling studies have enabled discoveries for metastatic prostate cancer (MPC) but have predominantly occurred in academic medical institutions and involved non-representative patient populations. We established the Metastatic Prostate Cancer Project (MPCproject, mpcproject.org), a patient-partnered initiative to involve patients with MPC living anywhere in the US and Canada in molecular research. Here, we present results from our partnership with the first 706 MPCproject participants. While 41% of patient partners live in rural, physician-shortage, or medically underserved areas, the MPCproject has not yet achieved racial diversity, a disparity that demands new initiatives detailed herein. Among molecular data from 333 patient partners (572 samples), exome sequencing of 63 tumor and 19 cell-free DNA (cfDNA) samples recapitulated known findings in MPC, while inexpensive ultra-low-coverage sequencing of 318 cfDNA samples revealed clinically relevant AR amplifications. This study illustrates the power of a growing, longitudinal partnership with patients to generate a more representative understanding of MPC.
MIT Department
Massachusetts Institute of Technology. Department of Biology
Terms of Use
Creative Commons Attribution-NonCommercial-NoDerivs License
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.1016/J.XGEN.2022.100169
